Nevisense to Be Included in a Large Clinical Study Initiated by The Ronald O. Perelman Department of Dermatology Clinic at NYU Langone Health

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Nevisense will be included in a large clinical study initiated by The Ronald O. Perelman Department of Dermatology clinic at NYU Langone Health. The news was announced today by SciBase Holding AB.

The SpotCheck study will investigate the use of Nevisense as a point-of-care diagnostic tool to assist with skin cancer detection in a remote setting such as a non-specialist practice or pharmacy. The study will evaluate how Nevisense can help providers assess patients’ irregular moles in such locations, and if successful will help improve access for patients to technology for the early detection of melanoma.

David Polsky, MD, PhD., the Alfred W. Kopf, M.D. Professor of Dermatologic Oncology at NYU Langone Health and Perlmutter Cancer Center will serve as the Primary Investigator for the study. “We are very interested in developing new methods to extend expert skin cancer diagnostic services to communities lacking access to in-person specialist care. We believe that Nevisense can help improve the accuracy of visual diagnosis in a telemedicine-based system”, says Dr. Polsky who is also Director of its Pigmented Lesion Section in the Ronald O. Perelman Department of Dermatology and a professor in the  Department of Pathology at NYU Langone.

Simon Grant, CEO of SciBase, stated, “We are delighted that NYU has selected Nevisense for this very important study. There is clearly a need for improved tools for non-specialists to assess atypical pigmented lesions. The objective data Nevisense provides may effectively help in remote settings such as pharmacies, and not only provide much-needed support for clinicians and patients but open up a significant new opportunity for SciBase.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles